Etoposid Ebewe

Etoposid Ebewe

etoposide

Manufacturer:

Sandoz

Distributor:

Zuellig
/
Firma Vai Hong
Concise Prescribing Info
Contents
Etoposide
Indications/Uses
Gonocyte tumours (testicular tumours, chorion carcinoma), ovarian carcinoma, small-cell & non-small-cell bronchial carcinoma, Hodgkin's disease & non-Hodgkin's lymphoma, acute myeloblastic leukemia, gastric carcinoma.
Dosage/Direction for Use
IV 50-100 mg/m2 for 5 consecutive days w/ a repetition after 2-3 wk; or 120-150 mg/m2 on day 1, 3 & 5 of the therapy, w/ a repetition of the therapy cycle after 2-3 wk. Oral 50 mg/m2 on days 1-21 w/ repetition on day 28; 4-6 repetitions should be carried out.
Contraindications
Hypersensitivity to podophylline & its derivatives. Severe hepatic & renal dysfunction; pregnancy & lactation; severe myelosuppression. Childn <2 yr.
Special Precautions
Previous myelosuppression therapy, varicella, herpes zoster, mucous membrane infections, MI. Alcohol abuse. Regular monitoring of haematologic parameters & blood levels. Mucous membrane infection; bone fractures. Orally vaccinated w/ poliovirus. May impair ability to drive or operate machinery.
Adverse Reactions
Inhibition of haematopoietic system, alopecia, GI upsets; hypotension, allergic reactions, neuropathy, anemia.
Drug Interactions
Cisplatin, carboplatin, mitomycin C, cyclophosphamide, carmustine (BCNU), vincristine, dactinomycin, cytosine arabinoside, buffer soln w/ pH >8.
ATC Classification
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Presentation/Packing
Form
Etoposid Ebewe infusion conc 100 mg/5 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in